United Health Products uplisted to OTCQB; FDA declines IDE for CelluSTAT study

United Health Products, Inc.

Common stock upgraded from OTC Pink to OTCQB effective May 1, 2025; ticker UEEC.
FDA declined to approve IDE for follow-on CelluSTAT clinical study, citing BIMO audit findings from initial 2019 study.
Company responded to audit findings in Oct 2024 and Apr 2025; teleconference with FDA scheduled within 10 days.
No assurance that FDA Premarket Approval for CelluSTAT will be granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.